IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Karl Emil Groth et al.

Attorney Docket: FCM1005USC2

Serial No.:

10/667,917

Group Art Unit: 3738

RECEIVED CENTRAL PAX SENTER

Filed:

September 22, 2003

Examiner: Thomas C. Barrett

JAN 2 5 2005

For:

TREATMENT OF HEPATITIS C USING HYPERTHERMIA

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to Sections 1.56, 1.97, and 1.98 of Title 37 of the Code of Federal Regulations, the following information is set forth in compliance with Applicants' duty of disclosure, as well as the duty of others substantively involved in the preparation of the above-titled application.

The Applicants and others substantively involved in the preparation of the application are aware of the documents listed on the enclosed PTO-1449 form. All of the listed documents were submitted or cited in parent application Serial No. 09/484,360, filed January 14, 2000, except for U.S. Patent Nos. 6,347,633 and 6,644,320, which are issued patents in the same family as this application.

Certification of Facsimile Transmission

I hereby certify that 2 pages including cover are being facsimile transmitted to the Patent and Trademark Office on the date shown below:

Signature:

Name: Joth Jung

Information Disclosure Statement Applicants: Karl Emil Groth et al. Serial Number: 10/667,917 Attorney Docket: FCM1005USC2

The present statement reflects the direct knowledge of the undersigned and information disclosed to the undersigned by the Applicants and others substantively involved in the preparation of the present application pursuant to their duty under 37 C.F.R. § 1.56.

Applicants reserve the right to show, pursuant to 37 C.F.R. § 1.131 or otherwise, that any one or more of the documents listed on the PTO-1449 form is not prior art to the present invention.

Pursuant to the Manual of Patent Examining Procedure, Chapter 609, Applicants request that the Examiner consider each of the listed documents and initial and return to the undersigned a copy of the enclosed PTO-1449 form.

It is believed that no fees are due in connection with this submission. However if this is incorrect, please charge any fees to Deposit Account No. 16-2312.

Date: January 25, 2005

Respectfully submitted,

Customer No. 009561

Patrick J. O'Connell (33,984)

POPOVICH, WILES &

O'CONNELL, P.A.

650 Third Avenue South, Suite 600

Minneapolis, MN 55402

Telephone: (612) 334-8989

Attorney for Applicants

Sheet 1 of 2.

FORM PTO-1449				U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY, DOCKET NO.		SERIAL NO.		
PATENT AND TR					אד ס	ADEMARK OF	FICE	FCM1005USC2	10/667,917					
		INFO	ORM	ATIO	N DI	SCLO	SUF ICAN	RE IT		APPLICANTS				
								•		Karl Groth et al.				****
(Use several sheets if necessary)								ary)	FILING DATE			GROUP		
									September 22, 2003			3738		
								U.S. PATE	ENT	DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER							DATE			CLASS	SUBÇLASS		DATE IF
	4	2	9	8_	0	0	6	11/03/81	Par					
	5	3	9	1	1	4	2	02/21/95		es et al.				
	5	4	8	6	2	0	8	01/23/96		sburg				
	5	6	7	4	1	9	0	10/07/97	Kel			<u> </u>		
	5	7	3	0.	7	2	0	03/24/98		es et al.		 		
	6	1	7	2	0	4	6	01/09/01		recht				
	6	3	4	7	6	3	3	02/19/02		oth et al.		-	<u> </u>	
	6	6	4	4	3	2	0	11/11/03	Gro	oth et al.		 		
				L				l	<u> </u>			<u> </u>	L	
							F	OREIGN PA	ATE	NT DOCUMENT	'S		•	
	DOCUMENT NUMBER					BER		DATE	COUNTRY CLASS		SUBCLASS TRANSLATION YES NO			
	DE 195 31 935 A1					02/20/97	Germany							
										· · · · · · · · · · · · · · · · · · ·				
								<u> </u>	_					<u></u>
	C	TH	ER	DO	CUN	/EN	TS	(including	Autl	hor, Title, Date,	Pertiner	nt Pages, E	tc.)	
	Γ	Т	1	\lon:	so e	t al.,	"W	nole-Body H	ypert	hermia and the A	ugmentati	on of Cellula	r Cytoto	oxic
	Alonso et al., "Whole-Body Hyperthermia and the Augmentation of Cellular Cytotoxic Responses in the Treatment of Acquired Immune Deficiency Syndrome," Southern									<u>n</u>				
		┶	_ 1	/ledi	cal.	Jour	<u>nal,</u>	88(10):\$142	(199	95).				
		İ		Alon: Capo	so e si's	t al., San	∵Sy com	sternic Hype a." Am. J. Cl	rtner lin. O	mia in the Treatm ncol. (CCT), 17(4	ent of HI\):353-359	/-related Dis: (1994).	seminal	ed
		-								mia in the Treatm			seminal	ted
	Ì									p of Patients Trea				w
		_ _								ermia," approxima				
										mia in the Treatm				
		+								ned & Pharmacoth lings, Site Visit Re				rmia
	in AIDS," National Institute of Allergy and Infectious Diseases, September 4, 1990 (5 pages).									, (0				
-	"Extracorporeal Whole Body Hyperthermia," First Circle Medical, Inc., Doc.													
	No. 1600002, 1999 (71 pages).													
	February 25, 1994 Letter from the Department of Health and Human Services								•-					
	forwarding the "Full Report of the Site Visit Report – Clinical Use of Hyperthermia in AIDS" (24 pages, including cover letter).						ın							
	Ц			コル	_12	T PO	903	moduling G	7461	ouer j.				

Sheet 2 of 2.

EXAMINER	DATE CONSIDERED
	Shecterle et al., "More on Hepatitis C", The Scientist, May 24, 1999.
	Surgeon General Supports Company's Effort to Develop a New Treatment for Patients with AIDS and Other Diseases" page 1, 1998.
	PR NEWSWIRE "C. Everett Koop Joins First Circle Medical Board Former U.S.
	Southern Medical Journal, 88(10):S142 (1995).
	Pontiggia et al., "Whole-Body Hyperthermia Followed by Beta Carotene Supplementation in Patients with Acquired Immune Deficiency Syndrome (AIDS),"
	Pontiggia et al., "Whole Body Hyperthermia Associated with Betacarotene Supplementation in Patients with AIDS," Biomed & Pharmacother, 5:263-265 (1995).
	More, "Hyperthermia Finds Little Effect," GMHC Treatment Issues, Volume 9, Number 11, November 1995 (2 pages).
	Logan et al., "Case Report, Total Body Hyperthermia in the Treatment of Kaposi's Sarcoma in an HIV Positive Patient," Med. Oncol. & Tumor Pharmacother, 8(1):45-47 (1991).
	Internal Medicine Specialists "From Mercury to Malaria to Penicillin: The History of the Treatment of Syphilis at the Mayo Clinic, 1916-1955" reprint of Journal of the American Academy of Dermatology, 1995; 32:255-261.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.